NKTR Covered Call Strategy
NKTR (Nektar Therapeutics), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR (Nektar Therapeutics) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.48B, a beta of 1.25 versus the broader market, a 52-week range of 7.99-109, average daily share volume of 1.1M, a public-listing history dating back to 1994, approximately 61 full-time employees. These structural characteristics shape how NKTR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.25 places NKTR roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a covered call on NKTR?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current NKTR snapshot
As of May 15, 2026, spot at $70.12, ATM IV 56.90%, IV rank 3.34%, expected move 16.31%. The covered call on NKTR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this covered call structure on NKTR specifically: NKTR IV at 56.90% is on the cheap side of its 1-year range, which means a premium-selling NKTR covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 16.31% (roughly $11.44 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NKTR expiries trade a higher absolute premium for lower per-day decay. Position sizing on NKTR should anchor to the underlying notional of $70.12 per share and to the trader's directional view on NKTR stock.
NKTR covered call setup
The NKTR covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NKTR near $70.12, the first option leg uses a $75.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NKTR chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NKTR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $70.12 | long |
| Sell 1 | Call | $75.00 | $3.08 |
NKTR covered call risk and reward
- Net Premium / Debit
- -$6,704.50
- Max Profit (per contract)
- $795.50
- Max Loss (per contract)
- -$6,703.50
- Breakeven(s)
- $67.05
- Risk / Reward Ratio
- 0.119
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
NKTR covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on NKTR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$6,703.50 |
| $15.51 | -77.9% | -$5,153.22 |
| $31.02 | -55.8% | -$3,602.94 |
| $46.52 | -33.7% | -$2,052.66 |
| $62.02 | -11.5% | -$502.37 |
| $77.52 | +10.6% | +$795.50 |
| $93.03 | +32.7% | +$795.50 |
| $108.53 | +54.8% | +$795.50 |
| $124.03 | +76.9% | +$795.50 |
| $139.54 | +99.0% | +$795.50 |
When traders use covered call on NKTR
Covered calls on NKTR are an income strategy run on existing NKTR stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
NKTR thesis for this covered call
The market-implied 1-standard-deviation range for NKTR extends from approximately $58.68 on the downside to $81.56 on the upside. A NKTR covered call collects premium on an existing long NKTR position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether NKTR will breach that level within the expiration window. Current NKTR IV rank near 3.34% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NKTR at 56.90%. As a Healthcare name, NKTR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NKTR-specific events.
NKTR covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NKTR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NKTR alongside the broader basket even when NKTR-specific fundamentals are unchanged. Short-premium structures like a covered call on NKTR carry tail risk when realized volatility exceeds the implied move; review historical NKTR earnings reactions and macro stress periods before sizing. Always rebuild the position from current NKTR chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on NKTR?
- A covered call on NKTR is the covered call strategy applied to NKTR (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With NKTR stock trading near $70.12, the strikes shown on this page are snapped to the nearest listed NKTR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NKTR covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the NKTR covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 56.90%), the computed maximum profit is $795.50 per contract and the computed maximum loss is -$6,703.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NKTR covered call?
- The breakeven for the NKTR covered call priced on this page is roughly $67.05 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NKTR market-implied 1-standard-deviation expected move is approximately 16.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on NKTR?
- Covered calls on NKTR are an income strategy run on existing NKTR stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current NKTR implied volatility affect this covered call?
- NKTR ATM IV is at 56.90% with IV rank near 3.34%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.